Overview

Evaluation of Different Types of HER2 Expression in Breast Cancer Using [99mTc]Tc -ZHER2:4107

Status:
ENROLLING_BY_INVITATION
Trial end date:
2026-03-30
Target enrollment:
Participant gender:
Summary
The study should evaluate the \[99mTc\]Tc -ZHER2:4107 accumulation in primary tumour of breast cancer patients with different HER2 expression
Phase:
PHASE2
Details
Lead Sponsor:
Tomsk National Research Medical Center of the Russian Academy of Sciences
Collaborator:
Uppsala University